• 1. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 2. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 3. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 4. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 5. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525

Recent Advances in the Application of 5-Ethyl-2-fluoro-3-iodopyridine (CAS: 1806414-85-6) in Chemical Biology and Pharmaceutical Research

5-Ethyl-2-fluoro-3-iodopyridine (CAS: 1806414-85-6) has emerged as a versatile building block in medicinal chemistry and chemical biology due to its unique structural features and reactivity. This halogenated pyridine derivative has garnered significant attention in recent years for its potential applications in drug discovery, particularly in the development of kinase inhibitors and radiopharmaceuticals. The presence of fluorine and iodine atoms at strategic positions on the pyridine ring enables diverse functionalization through cross-coupling reactions, making it a valuable intermediate for structure-activity relationship (SAR) studies.

Recent studies have demonstrated the utility of 5-Ethyl-2-fluoro-3-iodopyridine in the synthesis of novel heterocyclic compounds with promising biological activities. A 2023 publication in the Journal of Medicinal Chemistry reported its use as a key intermediate in the development of selective JAK3 inhibitors, showing improved potency and selectivity profiles compared to earlier generations of inhibitors. The electron-withdrawing effects of the fluorine atom were found to significantly influence the binding affinity to the ATP-binding site of the kinase, while the iodine atom served as a handle for further structural modifications.

In the field of radiopharmaceuticals, researchers have exploited the reactivity of the iodine moiety in 5-Ethyl-2-fluoro-3-iodopyridine for radioiodination procedures. A recent study published in Nuclear Medicine and Biology demonstrated its successful application in the synthesis of ¹²³I-labeled probes for imaging protein-protein interactions in vivo. The ethyl group at the 5-position was shown to enhance the lipophilicity of the resulting compounds, improving their blood-brain barrier penetration properties for neurological applications.

The synthetic accessibility of 5-Ethyl-2-fluoro-3-iodopyridine has also been improved through recent methodological advances. A 2024 report in Organic Process Research & Development described a scalable, one-pot synthesis route with improved yield (78%) and purity (>99%) compared to traditional methods. This development is particularly significant for industrial applications where large quantities of high-quality material are required for preclinical and clinical studies.

From a safety and pharmacokinetic perspective, recent ADME studies have shown that derivatives of 5-Ethyl-2-fluoro-3-iodopyridine generally exhibit favorable metabolic stability and low cytochrome P450 inhibition potential. However, researchers have noted that the iodine atom may contribute to increased molecular weight and potential off-target effects in some cases, suggesting that careful structural optimization is necessary during drug development.

Looking forward, the unique properties of 5-Ethyl-2-fluoro-3-iodopyridine continue to inspire innovative applications across multiple therapeutic areas. Current research directions include its incorporation into PROTAC (PROteolysis TArgeting Chimera) molecules for targeted protein degradation and its use in the development of covalent inhibitors through selective modification of the iodine position. These emerging applications highlight the compound's enduring value as a privileged scaffold in modern drug discovery.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)